Cambridge Pulmonary Hypertension Outcome Review: Difference between revisions
Content deleted Content added
JamesOAdams (talk | contribs) No edit summary |
JamesOAdams (talk | contribs) No edit summary |
||
| Line 17: | Line 17: | ||
== Use in Clinical Trials == |
== Use in Clinical Trials == |
||
The Cambridge Pulmonary Hypertension Outcome Review has been a useful tool in clinical trials as it allows researchers to assess whether new medication or therapy is effective. The CAMPHOR has been utilized in clinical trials which investigate the effects of treprostinil<ref>{{cite journal|last=Channick|first=Richard N.|coauthors=Voswinckel, Robert; Rubin, Lewis J.|title=Inhaled treprostinil: a therapeutic review|journal=Drug Design, Development and Therapy|date=24/01/2012|volume=6|pages=19-28|doi=10.2147/DDDT.S19281|url=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267519/|accessdate=2 October 2013}}</ref><ref>{{cite journal|last=Chen|first=Hubert|coauthors=Rosenzweig, Erika B.; Gotzkowsky, S Karl; Arneson, Carl; Nelsen, Andrew C.; Bourge, Robert C.|title=Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension|journal=Health And Quality Of Life Outcomes|date=2013|volume=11|issue=31|pages=1-8|doi=10.1186/1477-7525-11-31|url=http://www.hqlo.com/content/11/1/31|accessdate=2 October 2013}}</ref>, as well as trials which investigate sildenafil<ref>{{cite journal|last=Tay|first=Edgar L.W.|coauthors=Papaphylactou, Maria; Diller, Gerhard Paul; Alonso-Gonzalez, Rafael; Inuzuka, Ryo; Giannakoulas, Georgios; Harries, Carl; Wort, Stephen John; Swan, Lorna; Dimopoulos, Konstantinos; Gatzoulis, Michael A.|title=Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy|journal=International Journal of Cardiology|date=16/06/2011|volume=149|issue=3|pages=372-376|doi=10.1016/j.ijcard.2010.02.020|url=http://www.sciencedirect.com/science/article/pii/S0167527310000872#|accessdate=2 October 2013}}</ref><ref>{{cite journal|last=Suntharalingam|first=Jay|coauthors=Treacy, Carmen M.; Doughty, Natalie J.; Goldsmith, Kimberley; Soon, Elaine; Toshner, Mark R.; Sheares, Karen K.; Hughes, Rodney; Morrell, Nicholas W.; Pepke-Zaba, Joanna|title=Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary Hypertension|journal=CHEST|date=2008|volume=134|issue=2|pages=229-236|doi=10.1378/chest.07-2681|url=http://journal.publications.chestnet.org/article.aspx?articleid=1085998|accessdate=2 October 2013}}</ref>. |
|||
The Cambridge Pulmonary Hypertension Outcome Review has been a useful tool in clinical trials as it allows researchers to assess whether new medication or therapy is effective. The CAMPHOR has been utilized in clinical trials which investigate the effects of treprostinil (ref channick)(ref chen), as well as trials which investigate sildenafil (ref tay)(ref suntharalingam) |
|||
==References== |
==References== |
||
Revision as of 15:45, 2 October 2013
 | This article, Cambridge Pulmonary Hypertension Outcome Review, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |
The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) is a disease specific patient-reported outcome measure which assess quality of life of patients with pulmonary hypertension (PH)[1]. It was the first pulmonary hypertension specific questionnaire for assessing patient reported symptoms, quality of life and functioning[2].
History
The CAMPHOR questionnaire was developed by Galen Research in 2006[3] to allow for cost-utility analyses for treatments of PH[4]. The theoretical basis for the CAMPHOR is the needs-based model of quality of life, which states that quality of life is highest when an individual has the ability and capacity to satisfy their own needs[5].
Properties
The CAMPHOR is made up of 3 main dimensions which assess symptoms, functioning and quality of life (QoL)[6]. The symptom dimension is made up of 25 symptoms and is broken up into 3 subscales: energy, breathlessness and mood. The QoL scale has 25 items which focus on socialization, role, acceptance, self-esteem, independence, and security. The activity scale has 15 items. Response options include true and not true. Scores for QoL and symptoms range from 0-25, with higher scores indicating worse quality of life. Activity scores range from 0-30, with higher scores indicating more physical limitations[7].
Language Adaptations and Validations
Since the development of the CAMPHOR, it has been translated and validated into fourteen different languages[8], including Australian and New Zealand English[9], German[10] and Swedish[11].
Use in Clinical Trials
The Cambridge Pulmonary Hypertension Outcome Review has been a useful tool in clinical trials as it allows researchers to assess whether new medication or therapy is effective. The CAMPHOR has been utilized in clinical trials which investigate the effects of treprostinil[12][13], as well as trials which investigate sildenafil[14][15].
References
- ^ McKenna, Stephen P. (21/08/2008). "Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses" (PDF). Health and Quality of Life Outcomes. 6 (65): 1–8. doi:10.1186/1477-7525-6-65. Retrieved 2 October 2013.
{{cite journal}}: Check date values in:|date=(help); Unknown parameter|coauthors=ignored (|author=suggested) (help)CS1 maint: unflagged free DOI (link) - ^ Pope, Janet (11/2011). "Measures of Systemic Sclerosis (Scleroderma)". Arthritis Care & Research. 63 (S11): S98–S111. doi:10.1002/acr.20598. Retrieved 2 October 2013.
{{cite journal}}: Check date values in:|date=(help) - ^ McKenna, S.P. (2006). "The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): A measure of health-related quality of life and quality of life for patients with pulmonary hypertension" (PDF). Quality of Life Research. 15: 103–115. doi:10.1007/s11136-005-3513-4. Retrieved 2 October 2013.
{{cite journal}}: Unknown parameter|coauthors=ignored (|author=suggested) (help) - ^ Meads, D.M. (03/09/2008). "The responsiveness and validity of the CAMPHOR Utility Index". European Respiratory Journal. 32 (6): 1513–1519. doi:10.1183/09031936.00069708. Retrieved 2 October 2013.
{{cite journal}}: Check date values in:|date=(help); Unknown parameter|coauthors=ignored (|author=suggested) (help) - ^ Hunt, Sonja M. (10/1992). "The QLDS: A scale for the measurement of quality of life in depression". Health Policy. 22 (3): 307–319. Retrieved 2 October 2013.
{{cite journal}}: Check date values in:|date=(help); Unknown parameter|coauthors=ignored (|author=suggested) (help) - ^ McKenna, Stephen P. (2008). "Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses". Health And Quality Of Life Outcomes. 6 (65): 1–8. doi:10.1186/1477-7525-6-65. Retrieved 2 October 2013.
{{cite journal}}: Unknown parameter|coauthors=ignored (|author=suggested) (help)CS1 maint: unflagged free DOI (link) - ^ Matura, Lee Ann (13/11/2012). "Health-Related Quality of Life and Psychological States in Patients With Pulmonary Arterial Hypertension". Journal of Cardiovascular Nursing: 1–7. doi:10.1097/JCN.0b013e318275330d. Retrieved 2 October 2013.
{{cite journal}}: Check date values in:|date=(help); Unknown parameter|coauthors=ignored (|author=suggested) (help) - ^ "Measures Database". Galen-Research.com. Galen Research. Retrieved 2 October 2013.
- ^ Ganderton, Louise (11/2011). "Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Australian and New Zealand population". Respirology. 16 (8): 1235–1240. doi:10.1111/j.1440-1843.2011.02030.x. Retrieved 2 October 2013.
{{cite journal}}: Check date values in:|date=(help); Unknown parameter|coauthors=ignored (|author=suggested) (help) - ^ Cima, Katharina (09/2012). "The German adaptation of the Cambridge pulmonary hypertension outcome review (CAMPHOR)". Health and Quality of Life Outcomes. 10 (110): 1–8. doi:10.1186/1477-7525-10-110. Retrieved 2 October 2013.
{{cite journal}}: Check date values in:|date=(help); Unknown parameter|coauthors=ignored (|author=suggested) (help)CS1 maint: unflagged free DOI (link) - ^ Selimovic, Nedim (12/2012). "Adaptation and validation of the Cambridge pulmonary hypertension outcome review for Sweden". Scandinavian Journal of Public Health. 40 (8): 777–783. doi:10.1177/1403494812464445. Retrieved 2 October 2013.
{{cite journal}}: Check date values in:|date=(help); Unknown parameter|coauthors=ignored (|author=suggested) (help) - ^ Channick, Richard N. (24/01/2012). "Inhaled treprostinil: a therapeutic review". Drug Design, Development and Therapy. 6: 19–28. doi:10.2147/DDDT.S19281. Retrieved 2 October 2013.
{{cite journal}}: Check date values in:|date=(help); Unknown parameter|coauthors=ignored (|author=suggested) (help)CS1 maint: unflagged free DOI (link) - ^ Chen, Hubert (2013). "Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension". Health And Quality Of Life Outcomes. 11 (31): 1–8. doi:10.1186/1477-7525-11-31. Retrieved 2 October 2013.
{{cite journal}}: Unknown parameter|coauthors=ignored (|author=suggested) (help)CS1 maint: unflagged free DOI (link) - ^ Tay, Edgar L.W. (16/06/2011). "Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy". International Journal of Cardiology. 149 (3): 372–376. doi:10.1016/j.ijcard.2010.02.020. Retrieved 2 October 2013.
{{cite journal}}: Check date values in:|date=(help); Unknown parameter|coauthors=ignored (|author=suggested) (help) - ^ Suntharalingam, Jay (2008). "Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary Hypertension". CHEST. 134 (2): 229–236. doi:10.1378/chest.07-2681. Retrieved 2 October 2013.
{{cite journal}}: Unknown parameter|coauthors=ignored (|author=suggested) (help)